JP2025505933A - Ｍｓｌｎを標的とする抗原結合タンパク質及びその使用 - Google Patents

Ｍｓｌｎを標的とする抗原結合タンパク質及びその使用 Download PDF

Info

Publication number
JP2025505933A
JP2025505933A JP2024540577A JP2024540577A JP2025505933A JP 2025505933 A JP2025505933 A JP 2025505933A JP 2024540577 A JP2024540577 A JP 2024540577A JP 2024540577 A JP2024540577 A JP 2024540577A JP 2025505933 A JP2025505933 A JP 2025505933A
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
sequence shown
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024540577A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025505933A5 (https=
Inventor
ホァジン ワン
ヂェンウェイ ヂョン
チャオ チョン
アルミン シエ
シャオルイ チェン
シャオウェン フー
Original Assignee
オリセル セラピューティクス カンパニー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オリセル セラピューティクス カンパニー リミテッド filed Critical オリセル セラピューティクス カンパニー リミテッド
Publication of JP2025505933A publication Critical patent/JP2025505933A/ja
Publication of JP2025505933A5 publication Critical patent/JP2025505933A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4254—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K40/4255—Mesothelin [MSLN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2024540577A 2022-01-06 2023-01-06 Ｍｓｌｎを標的とする抗原結合タンパク質及びその使用 Pending JP2025505933A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN202210011545 2022-01-06
CN202210011545.7 2022-01-06
CN202210018557.2 2022-01-07
CN202210018557 2022-01-07
PCT/CN2023/070928 WO2023131276A1 (zh) 2022-01-06 2023-01-06 靶向msln的抗原结合蛋白及其应用

Publications (2)

Publication Number Publication Date
JP2025505933A true JP2025505933A (ja) 2025-03-05
JP2025505933A5 JP2025505933A5 (https=) 2026-01-06

Family

ID=87073247

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024540577A Pending JP2025505933A (ja) 2022-01-06 2023-01-06 Ｍｓｌｎを標的とする抗原結合タンパク質及びその使用

Country Status (5)

Country Link
US (1) US20250213691A1 (https=)
EP (1) EP4461747A4 (https=)
JP (1) JP2025505933A (https=)
CN (1) CN118510809A (https=)
WO (1) WO2023131276A1 (https=)

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104955845B (zh) * 2012-09-27 2018-11-16 美国政府(由卫生和人类服务部的部长所代表) 间皮素抗体和引起有效的抗肿瘤活性的方法
CN103819559B (zh) * 2013-12-10 2016-02-24 中国科学院武汉病毒研究所 一种抗间皮素纳米抗体及其编码基因和该纳米抗体的用途
US20170267755A1 (en) * 2016-03-16 2017-09-21 Sri International Isolated anti-mesothelin antibodies, conjugates and uses thereof
US20180002439A1 (en) * 2016-06-30 2018-01-04 Institut National De La Sante Et De La Recherche Medicale (Inserm) Anti-mesothelin antibodies and uses thereof
CN107840891A (zh) * 2016-09-19 2018-03-27 上海吉倍生物技术有限公司 高亲和力的抗msln抗体及其应用
EP3621994A4 (en) * 2017-05-12 2020-12-30 Harpoon Therapeutics, Inc. MESOTHELIN BINDING PROTEINS
WO2019043026A1 (en) * 2017-08-30 2019-03-07 INSERM (Institut National de la Santé et de la Recherche Médicale) ANTI-MESOTHELIC RADIOMARQUATED SINGLE DOMAIN ANTIBODIES SUITABLE FOR IMAGING AND TREATING CANCERS
KR101966362B1 (ko) * 2017-10-20 2019-04-05 주식회사 녹십자 항-msln 항체 및 이를 포함하는 암 치료용 약학적 조성물
CN108129566B (zh) * 2017-12-31 2021-05-11 中国科学院武汉病毒研究所 靶向间皮素的c-型单域抗体及其制备方法与应用
WO2019184886A1 (zh) * 2018-03-26 2019-10-03 上海原能细胞医学技术有限公司 促进免疫细胞增殖的方法
EP3806889A4 (en) * 2018-06-18 2022-07-13 Anwita Biosciences, Inc. CYTOKI FUSION PROTEINS AND USES THEREOF
CA3111087A1 (en) * 2018-08-29 2020-03-05 Nanjing Legend Biotech Co., Ltd. Anti-mesothelin chimeric antigen receptor (car) constructs and uses thereof
CN109111528B (zh) * 2018-09-20 2021-06-22 杭州普略生物科技有限公司 以msln为靶点的嵌合抗原受体
CA3125484A1 (en) * 2019-01-08 2020-07-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cross-species single domain antibodies targeting mesothelin for treating solid tumors
CN110698562B (zh) * 2019-10-31 2022-10-25 浙江蓝盾药业有限公司 抗人msln单克隆抗体
CN111349165B (zh) * 2020-05-25 2020-09-01 南京蓝盾生物科技有限公司 抗人msln单克隆抗体及其应用
CN112210008A (zh) * 2020-07-16 2021-01-12 上海恒润达生生物科技有限公司 一种新型抗人msln抗体及其用途
CN111560072B (zh) * 2020-07-16 2020-12-11 上海恒润达生生物科技有限公司 抗人msln抗体以及靶向msln的免疫效应细胞
CN112225811A (zh) * 2020-07-16 2021-01-15 上海恒润达生生物科技有限公司 新型抗人msln抗体及其用途
CN111848819A (zh) * 2020-07-31 2020-10-30 广东昭泰体内生物医药科技有限公司 一种靶向msln的嵌合抗原受体及其应用
CN118510890A (zh) * 2022-01-07 2024-08-16 原启生物科技(上海)有限责任公司 靶向cldn18.2和msln的嵌合抗原受体及其用途

Also Published As

Publication number Publication date
CN118510809A (zh) 2024-08-16
EP4461747A4 (en) 2026-04-15
WO2023131276A1 (zh) 2023-07-13
EP4461747A1 (en) 2024-11-13
US20250213691A1 (en) 2025-07-03

Similar Documents

Publication Publication Date Title
US11059890B2 (en) Anti-human PD-1 humanized monoclonal antibody and application thereof
AU2019275479B2 (en) Chimeric antigen receptors with modified linker domains and uses thereof
EP3363816A1 (en) Anti-ox40 antibody and application thereof
JP2018522564A (ja) 抗グリピカン３抗体およびその使用
JP2018528786A (ja) 腫瘍特異的抗ｅｇｆｒ抗体およびその使用
CN117229407B (zh) 一种靶向gprc5d的单域抗体、嵌合抗原受体及其应用
US20240384001A1 (en) Anti-gprc5d antigen binding protein and use thereof
US20250177527A1 (en) Chimeric antigen receptor targeting cldn18.2 and msln and use thereof
JP2025504803A (ja) Ｇｐｒｃ５ｄを標的とするキメラ抗原受容体及びその使用
CN113527493A (zh) 一种b7-h3抗体及其应用
CN116249559A (zh) 抗独特型组合物及其使用方法
CN112661857A (zh) 一种嵌合抗原受体及其用途
TW202317640A (zh) 一種抗人pd-l1人源化抗體或其抗原結合片段及其應用
WO2023024084A1 (zh) 一种嵌合抗原受体及其用途
JP2025505933A (ja) Ｍｓｌｎを標的とする抗原結合タンパク質及びその使用
CN113354737B (zh) 一种磷脂酰肌醇蛋白聚糖3抗体及其应用
CN116284389A (zh) 抗afp/hla02 tcr样抗体及其用途
JP2024500511A (ja) 抗ｐｄ－ｌ１抗体及びその使用
CN117241824A (zh) 改造的免疫效应细胞及其用途
CN113646433A (zh) 靶向抗TNF-α抗体的组合物和方法
WO2024088371A1 (zh) 靶向msln的抗原结合蛋白
EP4620974A1 (en) Anti-afp/hla02 tcr-like antibody and use thereof
WO2026026960A1 (zh) 一种靶向bcma的人源化纳米抗体及其应用
KR102685211B1 (ko) 항-c-Met 항체 또는 그의 항원 결합 단편을 포함하는 키메라 항원 수용체, 및 이의 용도
WO2025067388A1 (zh) 一种靶向cd79b的单域抗体和嵌合抗原受体及其应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251222

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251222